BreakingNews-GSK-LN-02
Email Sign Up
Give
Menu
Menu
En Español
Search Our Site
Home
Who We Are
About Us
Our Vision
Our History
Our Commitment to DE&I
Financials
Careers
Leadership and Partners
Board of Directors
Research Committee of the Board
SAB
Leadership and Partners
Executive Staff
Young Leaders Board
The Complexity of Lupus
Why Is Lupus So Complex?
About Lupus
Symptoms
Diagnosis
Treatment
Educational Resources
Our Research
Revolutionizing Research
Research Road Map
Research We Fund
Our Progress
Get Involved in Research
Lupus Therapeutics, LLC
For Researchers
Funding Opportunities
Funded Research
Research Partners
Scientific Resources
Research Contacts
LRA Reviewers 2021 - 2022
News and Events
News
Research and Clinical Trial News
Grant Updates
Learn From Lupus — COVID-19
Press Releases
Events
For Media
Get Involved
Give
Online Donation
Other Ways to Give
Research
Find a Clinical Trial
Give to the Lupus Brain Bank
Events
Join Our Events
Walk
Host an Event
Volunteer
Educate Your Community
Advocate
Advocate
Results
Advocacy News
Community
Community Forum
Community Blog
Lupus Stories
Contact
Home
Acerca del Lupus
¿Qué es el lupus?
Síntomas comunes del lupus
Diagnóstico y tratamiento
Diagnóstico
Prueba de ANA
Tratamiento
Donate
Sign up for Updates
BreakingNews-GSK-LN-02
Related Posts
Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network
READ MORE
Thank You for Making a Difference During Lupus Awareness Month
READ MORE
EULAR Presentation Showed Upadacitinib Improved Lupus Disease Activity
READ MORE
Post navigation
LRA Pleased to Share GSK’s Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA
Learn and connect with our community!
Help Us Find a Cure
For Lupus Research
Search Our Site
X
